logo-loader

Autolus Ltd

Receive alerts
Market:
NASDAQ
Market Cap:
$530.34 m
Price
11.79 USD
Change
5.55%
52 weeks high
48.00
52 weeks low
9.53

In brief

Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.
Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.